What the FDA Relabeling of Abacavir Means for You and Your Patient

HLA-B*5701 Correlations

November 2008

The HLA-B*5701 allele is involved in hypersensitivity reaction with abacavir in 5-8% of patients who initiate therapy. Prevalence of the HLA-B*5701 allele varies among racial groups; however, the point is it is present in all racial and ethnic groups that have been tested to some extent. Consequently, all patients who are going to be receiving this drug should be tested for this specific allele. And there are very high odds ratio for abacavir hypersensitivity reaction when the patient carries the HLA-B*5701 allele.

< Previous Slide

HLA-B*5701 Correlations

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?